Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma
Clinical trial NCT04055753 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04055753
- Sponsor
- Fox Chase Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2016-08-12
- Primary completion
- 2026-10-15
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.